Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Does distance to the hospital affect the course of treatment and follow-up for children with Acute Lymphoblastic Leukemia?","authors":"Cecilie Bjerregaard Brix, Mette Bitsch Linck Hansen, Rikke Io Jessen, Cecilie Møller Høymark, Regitze Gyldenholm Skals, Søren Hagstrøm, Ninna Brix","doi":"10.1007/s00432-025-06127-8","DOIUrl":"10.1007/s00432-025-06127-8","url":null,"abstract":"<p><strong>Purpose: </strong>Centralization of specialized healthcare including treatment of children with acute lymphoblastic leukemia (ALL) has increased in high-income countries. We aimed to clarify whether the distance to the hospital for children with ALL affects the course of treatment regarding the number and duration of hospitalizations, outpatient clinic visits, missed appointments in the outpatient clinic, the duration of follow-up, or survival.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of children diagnosed with ALL aged 0-14 at Aalborg University Hospital from 1996 to 2018. Data was collected through registries and medical records. Comparisons of cancer- and sociodemographic characteristics in children with long versus short distance were made, divided at 42 km. Outcome variables were assessed by correlation and regression analyses. We compared overall survival using Kaplan-Meier.</p><p><strong>Results: </strong>The cohort consisted of 95 children. Cancer- and sociodemographic characteristics of the children with long versus short distance were similar, though the children with long distance were older and had less infections during treatment. There was no significant difference between the two groups regarding the number of hospitalizations, outpatient clinic visits, missed appointments, the duration of follow-up, or survival. Though, the summarized length of hospitalization was shorter for the group with long distance, when adjusting for age (-23 days (95% CI -45;-1)).</p><p><strong>Conclusion: </strong>No significant differences between the course of treatment and follow-up for children with long and short distance to the hospital was revealed, except for a shorter summarized length of hospitalization for children with long distance.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"76"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global evolution of breast cancer incidence in childbearing-age women aged 15-49 years: a 30-year analysis.","authors":"Chengwei Xia, Yini Liu, Wei Yong, Xin Qing","doi":"10.1007/s00432-025-06113-0","DOIUrl":"10.1007/s00432-025-06113-0","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) poses an increasing threat to women's health, yet its characteristics in women of childbearing age (WCBA) are infrequently reported. This study aims to investigate the patterns and trends in BC incidence among WCBA over the past decades.</p><p><strong>Materials and methods: </strong>This study focuses on BC incidence in women aged 15-49 years, consistent with the WHO definition of WCBA. Estimates and 95% uncertainty intervals (UIs) for BC incidence in WCBA were obtained from the Global Burden of Diseases Study 2021. We utilized an age-period-cohort (APC) model to estimate the overall annual percentage change in incidence (net drift, % per year) and the annual percentage change within each age group (local drift, % per year). This model also provided fitted longitudinal age-specific rates adjusted for period deviations (age effects) and period/cohort relative risks (period/cohort effects) from 1992 to 2021.</p><p><strong>Results: </strong>In 2021, the global incidence of BC among WCBA was 561.44 thousand (95% UI 519.76 to 606.99). Between 1992 and 2021, the estimated annual change in BC incidence among WCBA was 0.47 (95% CI 0.41-0.52) worldwide, ranging from -0.43 (95% CI -0.54--0.31) in High sociodemographic index (SDI) region to 2.03 (95% CI 1.97-2.1) in Low-middle SDI region. Local drift analysis showed that higher SDI regions had higher age-standardized incidence rates among WCBA, with age effects demonstrating similar patterns across different SDI regions and increasing risk with age. Notably, the rising trend in BC incidence among WCBA occurs at progressively younger ages. Globally, unfavorable period and cohort effects were observed. All SDI regions exhibited increased period and cohort risks, except for the High SDI region, which saw a reduction in incidence rates influenced by period and cohort effects, particularly among those born after 1996.</p><p><strong>Conclusion: </strong>The increasing incidence of BC among WCBA highlights the urgent need for effective intervention and preventive policies to alleviate this growing global burden.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"75"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin.","authors":"John S Wang, Jack C Shapiro, Sarah Orlando, Rusul Al-Marayaty, Farres Obeidin, David VanderWeele, Haris Charalambous, Seth M Pollack, Pedro Hermida de Viveiros","doi":"10.1007/s00432-025-06102-3","DOIUrl":"10.1007/s00432-025-06102-3","url":null,"abstract":"<p><strong>Background: </strong>Desmoplastic small round cell tumor is a rare sarcoma type with poor prognosis for which there is no standard of care. It primarily affects adolescents and young adults and treatment is both multimodal and challenging due to the aggressive nature of the disease.</p><p><strong>Case presentation: </strong>we describe a case of a 27-year-old male who presented with hematuria and a five-centimeter mass on his bladder wall. His case details an especially challenging diagnosis as the pathology and IHC raised the suspicion for a poorly differentiated urothelial carcinoma until next-generation sequencing revealed the ESWR1::WT1 fusion gene rearrangement pathognomonic for desmoplastic small round cell tumor. After failing multiple lines of chemotherapy and also pembrolizumab, the patient was started on enfortumab-vedotin (EV), an antibody-drug conjugate targeting Nectin-4. Patient sustained partial response and documented disease control with clinical benefit for 23 months. Later, IHC staining of the tumor for nectin-4 was found to be moderately positive.</p><p><strong>Conclusion: </strong>This case report is the first documented usage of EV in the management of a desmoplastic small round cell tumor case and gives light to a new potential therapeutic strategy for this rare and aggressive tumor.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"73"},"PeriodicalIF":2.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation sequencing based deep learning model for prediction of HER2 status and response to HER2-targeted neoadjuvant chemotherapy.","authors":"Jia Wang, Ge Gao, Cong Tian, Jiao Zhang, De-Chuang Jiao, Zhen-Zhen Liu","doi":"10.1007/s00432-025-06105-0","DOIUrl":"10.1007/s00432-025-06105-0","url":null,"abstract":"<p><strong>Introduction: </strong>For patients with breast cancer, the amplification of Human Epidermal Growth Factor 2 (HER2) is closely related to their prognosis and treatment decisions. This study aimed to further improve the accuracy and efficiency of HER2 amplification status detection with a deep learning model, and apply the model to predict the efficacy of neoadjuvant therapy.</p><p><strong>Methods: </strong>We combined Next-Generation Sequencing (NGS) data and IHC staining images of 606 breast cancer patients and developed a Vision Transformer (ViT) deep learning model to identify the amplification of HER2 through these IHC staining images. This model was then applied to predict the efficacy of neoadjuvant therapy in 399 HER2-positive breast cancer patients.</p><p><strong>Results: </strong>The NGS data of 606 patients were split into training (N = 404), validation (N = 101), and testing (N = 101) sets. The top 3 genes with highest mutation frequency were TP53, ERBB2 and PIK3CA. With the NGS results as deep learning model labels, the accuracy of our ViT model was 93.1% for HER2 amplification recognition. The misidentifications was likely due to the heterogeneity of HER2 expression in cancer tissues. For predicting the efficacy of neoadjuvant therapy, receiver operating characteristic (ROC) curves were plotted, and the combination of image recognition result and clinical pathological features yielded an area under the curve (AUC) value of 0.855 in the training set and 0.841 in the testing set.</p><p><strong>Conclusions: </strong>Our study provided a method of HER2 status recognition based on IHC images, improving the efficiency and accuracy of HER2 status assessment, and can be used for predicting the efficacy of anti-HER2 targeted neoadjuvant therapy. We intend our deep learning model to assist pathologists in HER2 amplification recognition.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"72"},"PeriodicalIF":2.7,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive diagnostic tool for histopathological classification of congenital mesoblastic nephroma based in molecular genetic findings.","authors":"Hiroshi Hamada, Kenichi Kohashi, Takeshi Iwasaki, Mikiko Hashisako, Yuko Hino, Masahiro Fukuhara, Amane Kamouchi, Naonori Kawakubo, Tatsuro Tajiri, Yoshinao Oda","doi":"10.1007/s00432-025-06116-x","DOIUrl":"10.1007/s00432-025-06116-x","url":null,"abstract":"<p><strong>Purpose: </strong>Congenital mesoblastic nephromas (CMN) are histologically classified into classical, cellular, and mixed subtypes. Most cellular CMNs harbor ETV6-NTRK3 gene fusions, and classic and mixed CMNs harbor EGFR internal tandem duplications (EGFR-ITDs). Classic CMNs are considered benign, whereas recurrent or metastatic diseases occur in the cellular subtypes. Direct identification of mutations is desirable for an accurate diagnosis. However, molecular genetic analyses cannot be performed in a number of histopathology laboratories. This study aimed to investigate a surrogate marker for the accurate histological classification of CMN.</p><p><strong>Methods: </strong>Overall, 11 CMN cases diagnosed at our institute were included in this study. Reverse transcription-polymerase chain reaction was performed for the NTRK gene fusion and EGFR-ITDs in all cases. Comprehensive mRNA analysis was performed using the nCounter^® Gene Expression Assay. Principal component analysis (PCA) was performed based on the gene expression levels. Immunohistochemical evaluation was conducted for the expression of p-Mek1/2, p-Erk1/2, and EGFR.</p><p><strong>Results: </strong>PCA revealed differences in mutation patterns between the EGFR-ITDs and NTRK fusion tumor groups. Gene ontology analysis of the highly expressed genes in the EGFR-ITDs tumor group revealed enrichment related to the mitogen-activated protein kinase (MAPK) signaling pathway. p-Mek1/2 and p-Erk1/2 immunoreactivity was significantly increased in the EGFR-ITDs tumor group (p = 0.018 and p = 0.017, respectively). EGFR immunoreactivity is not a useful marker for CMN with EGFR-ITD.</p><p><strong>Conclusion: </strong>p-Mek1/2 and p-Erk1/2 immunoreactivity may be useful markers for EGFR-ITDs. Thus, MEK1/2 inhibitors possess the potential to be used as a targeted therapy for CMN with EGFR-ITDs.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"69"},"PeriodicalIF":2.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bufalin targets the SRC-3/c-Myc pathway in chemoresistant cells to regulate metastasis induced by chemoresistance in colorectal cancer.","authors":"Jinbao Chen, Chenqi Wu, Kun Yu, Jinpei Liu, Jiahua Yang, Wei Li, Xiaoxia Tang, Yihai Shi, Ke Xu, Yi Chen, Xiaoyu Qin","doi":"10.1007/s00432-025-06124-x","DOIUrl":"10.1007/s00432-025-06124-x","url":null,"abstract":"<p><strong>Background: </strong>Metastasis and chemoresistance are often major challenges in advanced-stage colorectal cancer. Bufalin has a therapeutic effect on both metastasis and drug resistance, but how bufalin affects chemoresistance-mediated metastasis remains unclear.</p><p><strong>Methods: </strong>The role of BU in the inhibition of EMT and angiogenesis induced by chemoresistant cells using wound healing assays, invasion assays, HUVEC tube formation and adhesion assays. Western blot and immunofluorescence were used to explore the potential molecular changes. BU can precisely regulate c-Myc expression by targeting SRC-3 in chemoresistant cells was confirmed by Western blot. In vivo experiments were conducted to validate that both BU and cinobufacini can ameliorate drug resistance-promoted EMT and angiogenic effects.</p><p><strong>Results: </strong>Bufalin inhibited resistance-induced epithelial-mesenchymal transition (EMT) and angiogenesis. Targeting of the SRC-3 protein by bufalin reduced the expression level of c-Myc and inhibited the prometastatic effect mediated by chemoresistance, and overexpression of SRC-3 or c-Myc reversed the inhibitory effect of bufalin on chemotherapeutic resistance, promoting metastasis. Moreover, the clinical drug cinobufacini and its main active monomer bufalin reduced liver metastasis of colorectal cancer caused by chemoresistance in vivo.</p><p><strong>Conclusion: </strong>Bufalin can target the SRC-3/c-Myc signaling pathway to affect the prometastatic effect of chemoresistant cells, suggesting that bufalin may be used as a new adjuvant antimetastatic therapy for colorectal cancer.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"71"},"PeriodicalIF":2.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: NR3C2 affects the proliferation and invasiveness of colon cancer cells through the Wnt/β-Catenin signaling pathway.","authors":"Ke Nie, Zhong-Jiang He, Ling-Jun Kong","doi":"10.1007/s00432-025-06129-6","DOIUrl":"10.1007/s00432-025-06129-6","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"70"},"PeriodicalIF":2.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database.","authors":"Bilu Li, Yuyan Wu, Yanhong Zhang, Chengyun Hu, Xue Li, Shanshan Luo, Chenyu Sun, Iyad Yousef, Yefei Wang, Chaoliang Tang","doi":"10.1007/s00432-025-06084-2","DOIUrl":"10.1007/s00432-025-06084-2","url":null,"abstract":"<p><strong>Background: </strong>In recent years, due to various risk factors, the incidence, prevalence, and mortality rates of female lung cancer have been increasing in both China and globally. This has become a significant public health challenge worldwide. Lung cancer not only poses a severe threat to women's health but also places a heavy burden on families and society.</p><p><strong>Objective: </strong>To conduct an in-depth analysis of the trends in disease burden for female lung cancer in China and globally from 1990 to 2021 and to forecast the next 15 years (2022-2037). The aim is to provide a reliable theoretical basis and reference value for clinical research and practice in female lung cancer and offer guidance for resource allocation and policy-making in society.</p><p><strong>Methods: </strong>Based on the Global Burden of Disease (GBD) 2021 database, we analyzed the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of lung cancer in China and globally from 1990 to 2021. These metrics were stratified by gender (BOTH, MALE, FEMALE), and the average annual percentage change (AAPC) was calculated for each metric over this period. The JOINPOINT regression model was used to analyze the trends in female lung cancer in China and globally from 1990 to 2021. The ARIMA model was applied to forecast the changes in age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASDR) for the next fifteen years (2022-2037) for female lung cancer in China and globally.</p><p><strong>Results: </strong>The results indicate an upward trend in incidence, prevalence, mortality, and DALYs for lung cancer in China. Globally, the prevalence of lung cancer showed an increasing trend, while the incidence, mortality, and DALYs demonstrated a declining trend. Both in China and globally, the incidence, prevalence, mortality, and DALY trends for female lung cancer were higher than those for males. From 1990 to 2021, the incidence, prevalence, mortality, and DALYs of female lung cancer in China exhibited an upward trend, with AAPC growth rates of 1.151%, 2.086%, 0.508%, and 0.210%, respectively. Similarly, globally, the incidence, prevalence, and mortality of female lung cancer also showed an upward trend, with growth rates of 0.576%, 1.123%, and 0.276%, respectively, while DALYs showed a slight decline with an AAPC of -0.029%.</p><p><strong>Conclusion: </strong>Although the overall disease burden of female lung cancer is not as high as that of males, the growth rate for female lung cancer is significantly higher than that for males both in China and globally. The overall disease burden and the growth rates of incidence and prevalence of female lung cancer in China are higher than the global average.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"68"},"PeriodicalIF":2.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying factors for pembrolizumab eligibility in head and neck cancer.","authors":"Satoru Miyamaru, Daizo Murakami, Kohei Nishimoto, Yorihisa Orita","doi":"10.1007/s00432-025-06121-0","DOIUrl":"10.1007/s00432-025-06121-0","url":null,"abstract":"<p><strong>Purpose: </strong>Although immune checkpoint inhibitors (ICIs) are used as first-line treatments for recurrent or metastatic head and neck cancer (R/M HNC), there are many cases where the treatment is ineffective, making the assessment of efficacy crucial. In this study, we examined factors associated with the therapeutic effects of pembrolizumab.</p><p><strong>Methods: </strong>We retrospectively analyzed 54 patients with R/M HNC treated with pembrolizumab from January 2020 to December 2022. We investigated the relationship between survival rates and various factors such as the combined positive score (CPS), histological subtypes, recurrent lesions, details of administered agents, sequence of administration, history of cetuximab use, and presence of immune-related adverse events (irAEs).</p><p><strong>Results: </strong>The overall survival rates at 1-, 2, and 3 years were 57.4%, 41.8%, and 32.3%, respectively. The response and disease control rates were 31.5% and 51.9%, respectively. In the univariate analysis, a CPS of 20 or higher, first-line treatment, no history of cetuximab use, and the presence of irAEs was associated with better survival rates, whereas in the multivariate analysis, the first two factors were significantly associated with better survival. In this study, 16 of 20 cases had a CPS of 50 or higher, and 7 had a CPS of 90 or higher, indicating that a large number of high CPS cases were included, which is believed to have contributed to the results of this study.</p><p><strong>Conclusion: </strong>In patients with a CPS of 20 or higher, pembrolizumab can be administered as first-line treatment, with favorable expected therapeutic effects.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"67"},"PeriodicalIF":2.7,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CircWDR78 inhibits the development of colorectal cancer by regulating the miR-653-3p/RGS4 axis.","authors":"Chu Hao, Yunju Pu, Jiunian Li, Zhi Zhong, Zhaohui Huang, Xue Wang","doi":"10.1007/s00432-025-06092-2","DOIUrl":"10.1007/s00432-025-06092-2","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) stands as one of the most serious threats to human health, with its mortality rate increase during the past years. Low diagnostic accuracy, poor prognosis, and high recurrence rates attributed to the high mortality rate of CRC. Consequently, the urgency to identify potential diagnose and biological targets for intervention in this disease. Among the various molecular factor associated with this disease, circular RNAs (circRNAs) have been a hot topic. These noncoding RNA molecules, characterized by their unique closed loop structure, displayed close associations with the progression of tumors.</p><p><strong>Methods: </strong>Actinomycin D experiment and RNA digestion experiment were used to verify the circular structure characteristics of circWDR78. Proliferation and motility ability of circWDR78 was evaluated by in vitro functional experiment. We also used RNA-seq technology to explore the signal pathways and genes it might regulate. Finally, the luciferase assay and qRT-PCR experiment proved that circWDR78 could sponge miR-653-3p, and confirmed that RGS4 is the downstream target of miR-653-3p.</p><p><strong>Results: </strong>This study demonstrated that circWDR78 is lower expression in colorectal cancer tissues, revealing its capacity to inhibit proliferation, colony forming ability and cell motility. These findings hint at a potential correlation between its downregulation and the progression of CRC. Mechanistically, we found that circWDR78 could sponge miR-653-3p and identified RGS4 as a novel target of miR-653-3p.</p><p><strong>Conclusion: </strong>This discovery highlights the significance of circWDR78 as a potential regulatory axis of miR-653-3p/RGS4 in CRC progression.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"66"},"PeriodicalIF":2.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}